Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 1
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean krzysztof milewski (141 results)?
Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy.
Borek B, Nowicka J, Gzik A, Dziegielewski M, Jedrzejczak K, Brzezinska J, Grzybowski M, Stanczak P, Pomper P, Zagozdzon A, Rejczak T, Matyszewski K, Golebiowski A, Olczak J, Lisiecki K, Tyszkiewicz M, Kania M, Piasecka S, Cabaj A, Dera P, Mulewski K, Chrzanowski J, Kusmirek D, Sobolewska E, Magdycz M, Mucha L, Masnyk M, Golab J, Nowotny M, Nowak E, Napiorkowska-Gromadzka A, Pikul S, Jazwiec R, Dzwonek K, Dobrzanski P, Meyring M, Skowronek K, Iwanowski P, Zaslona Z, Blaszczyk R. Borek B, et al. Among authors: mulewski k. Mol Cancer Ther. 2023 Jul 5;22(7):807-817. doi: 10.1158/1535-7163.MCT-22-0721. Mol Cancer Ther. 2023. PMID: 36939275
Design, Synthesis, and Development of pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part I-Indole Derivatives.
Stypik M, Zagozda M, Michałek S, Dymek B, Zdżalik-Bielecka D, Dziachan M, Orłowska N, Gunerka P, Turowski P, Hucz-Kalitowska J, Stańczak A, Stańczak P, Mulewski K, Smuga D, Stefaniak F, Gurba-Bryśkiewicz L, Leniak A, Ochal Z, Mach M, Dzwonek K, Lamparska-Przybysz M, Dubiel K, Wieczorek M. Stypik M, et al. Among authors: mulewski k. Pharmaceuticals (Basel). 2022 Jul 30;15(8):949. doi: 10.3390/ph15080949. Pharmaceuticals (Basel). 2022. PMID: 36015098 Free PMC article.
Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II-Benzimidazole Derivatives.
Stypik M, Michałek S, Orłowska N, Zagozda M, Dziachan M, Banach M, Turowski P, Gunerka P, Zdżalik-Bielecka D, Stańczak A, Kędzierska U, Mulewski K, Smuga D, Maruszak W, Gurba-Bryśkiewicz L, Leniak A, Pietruś W, Ochal Z, Mach M, Zygmunt B, Pieczykolan J, Dubiel K, Wieczorek M. Stypik M, et al. Among authors: mulewski k. Pharmaceuticals (Basel). 2022 Jul 27;15(8):927. doi: 10.3390/ph15080927. Pharmaceuticals (Basel). 2022. PMID: 36015075 Free PMC article.
Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma.
Gunerka P, Gala K, Banach M, Dominowski J, Hucz-Kalitowska J, Mulewski K, Hajnal A, Mikus EG, Smuga D, Zagozda M, Dubiel K, Pieczykolan J, Zygmunt BM, Wieczorek M. Gunerka P, et al. Among authors: mulewski k. PLoS One. 2020 Jul 23;15(7):e0236159. doi: 10.1371/journal.pone.0236159. eCollection 2020. PLoS One. 2020. PMID: 32702053 Free PMC article.
Structure-Based Discovery of High-Affinity Small Molecule Ligands and Development of Tool Probes to Study the Role of Chitinase-3-Like Protein 1.
Czestkowski W, Krzemiński Ł, Piotrowicz MC, Mazur M, Pluta E, Andryianau G, Koralewski R, Matyszewski K, Olejniczak S, Kowalski M, Lisiecka K, Kozieł R, Piwowar K, Papiernik D, Nowotny M, Napiórkowska-Gromadzka A, Nowak E, Niedziałek D, Wieczorek G, Siwińska A, Rejczak T, Jędrzejczak K, Mulewski K, Olczak J, Zasłona Z, Gołębiowski A, Drzewicka K, Bartoszewicz A. Czestkowski W, et al. Among authors: mulewski k. J Med Chem. 2024 Mar 14;67(5):3959-3985. doi: 10.1021/acs.jmedchem.3c02255. Epub 2024 Mar 1. J Med Chem. 2024. PMID: 38427954
Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists.
Pankiewicz P, Szybiński M, Kisielewska K, Gołębiowski F, Krzemiński P, Rutkowska-Włodarczyk I, Moszczyński-Pętkowski R, Gurba-Bryśkiewicz L, Delis M, Mulewski K, Smuga D, Dominowski J, Janusz A, Górka M, Abramski K, Napiórkowska A, Nowotny M, Dubiel K, Kalita K, Wieczorek M, Pieczykolan J, Matłoka M. Pankiewicz P, et al. Among authors: mulewski k. Pharmaceuticals (Basel). 2021 Jul 21;14(8):704. doi: 10.3390/ph14080704. Pharmaceuticals (Basel). 2021. PMID: 34451801 Free PMC article.
Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer.
Popiel D, Stańczak A, Skupińska M, Mikołajczyk A, Stańczak P, Mituła F, Hucz-Kalitowska J, Jastrzębska K, Smuga D, Dominowski J, Delis M, Mulewski K, Pietruś W, Zdżalik-Bielecka D, Dzwonek K, Lamparska-Przybysz M, Yamani A, Olejkowska P, Piórkowska N, Dubiel K, Wieczorek M, Pieczykolan J. Popiel D, et al. Among authors: mulewski k. Front Oncol. 2024 Jan 12;13:1293728. doi: 10.3389/fonc.2023.1293728. eCollection 2023. Front Oncol. 2024. PMID: 38282676 Free PMC article.